• PN: A211155

COMPONENTS

45x Ab-conjugated beads (S4P8 - Mouse IL-28A/B Ab-bead). PN: B211155A. One vial containing 100 µL of anti-mouse IL-28A/B conjugated to AimPlex Bead S4P8.

25x Biotin-detection Ab (Mouse IL-28A/B Biotin-dAb). PN: B211155B. One vial containing 100 µL of biotinylated anti-mouse IL-28A/B.

Lyophilized Standard Mix - Mouse Group 2 Panel B, 8-Plex. PN: MG20008. One vial containing lyophilized recombinant mouse G-CSF, GM-CSF, IL-28A/B, M-CSF, MIP-1α, MIP-1β, OSM, and TSLP.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human MouseIL-28A/IFN-lambda 2/IFNλ2. Can be multiplexed with other analytes in Mouse Group 2. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201)and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pgmL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 2: Negligible

Sample volume: 15 µL/test

Description:

IL-28A belongs to the IFN-λ family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN-λ1), IL-28A (IFN-λ2), and IL-28B (IFN-λ3), and are also known as the type III Interferons. IL-28A displays antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression. IL-28A also exhibits anti-proliferative and antitumor effects, making them a possible alternative to IFN-α cancer therapy. Unlike the type I IFNs, which are able to stimulate most cells, response to IFN-λ stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN-λR1. Another notable difference is the ability of the IFN-λ stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T-cells, suggesting a possible immunoregulatory role.

References:

1.      Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010 Aug;21(4):237-51.

2.      Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008 May;83(5):1181-93.

3.      Uze G and Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007 Jun-Jul;89(6-7):729-34.

4.      Mennechet FJ and Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006 Jun 1;107(11):4417-23.

5.      Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005 Feb 15;174(4):1932-7.